MDM2-BCL-XL PROTACs enable degradation of BCL-XL and stabilization of p53
Inhibition or degradation of the anti-apoptotic protein BCL-XL is a viable strategy for cancer treatment. Despite the recent development of PROTACs for degradation of BCL-XL, the choice of E3 ligase has been restricted to VHL and CRBN. Herein, we report the development of MDM2-BCL-XL PROTACs using M...
Uloženo v:
| Hlavní autoři: | , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Compuscript Ltd
2022-08-01
|
| Edice: | Acta Materia Medica |
| Témata: | |
| On-line přístup: | https://www.scienceopen.com/hosted-document?doi=10.15212/AMM-2022-0022 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|